These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 15579024)
1. The dichotomous role of nitric oxide in the pathogenesis of accelerated atherosclerosis associated with systemic lupus erythematosus. Levesque MC; Weinberg JB Curr Mol Med; 2004 Nov; 4(7):777-86. PubMed ID: 15579024 [TBL] [Abstract][Full Text] [Related]
2. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Belmont HM; Levartovsky D; Goel A; Amin A; Giorno R; Rediske J; Skovron ML; Abramson SB Arthritis Rheum; 1997 Oct; 40(10):1810-6. PubMed ID: 9336415 [TBL] [Abstract][Full Text] [Related]
3. Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus. Al Gadban MM; German J; Truman JP; Soodavar F; Riemer EC; Twal WO; Smith KJ; Heller D; Hofbauer AF; Oates JC; Hammad SM Cell Immunol; 2012; 276(1-2):42-51. PubMed ID: 22560558 [TBL] [Abstract][Full Text] [Related]
4. The role of nitric oxide in tissue destruction. Abramson SB; Amin AR; Clancy RM; Attur M Best Pract Res Clin Rheumatol; 2001 Dec; 15(5):831-45. PubMed ID: 11812024 [TBL] [Abstract][Full Text] [Related]
5. IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. Buie JJ; Renaud LL; Muise-Helmericks R; Oates JC J Immunol; 2017 Sep; 199(6):1979-1988. PubMed ID: 28779021 [TBL] [Abstract][Full Text] [Related]
6. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Sumi D; Hayashi T; Thakur NK; Jayachandran M; Asai Y; Kano H; Matsui H; Iguchi A Atherosclerosis; 2001 Apr; 155(2):347-57. PubMed ID: 11254905 [TBL] [Abstract][Full Text] [Related]
7. Role of endothelial dysfunction in atherosclerosis. Davignon J; Ganz P Circulation; 2004 Jun; 109(23 Suppl 1):III27-32. PubMed ID: 15198963 [TBL] [Abstract][Full Text] [Related]
8. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Tu H; Li Q; Xiang S; Jiang H; Mao Y; Shou Z; Chen J Atherosclerosis; 2012 May; 222(1):29-33. PubMed ID: 22417842 [TBL] [Abstract][Full Text] [Related]
17. [Arginine and statins: relationship between the nitric oxide pathway and the atherosclerosis development]. Rasmusen C; Cynober L; Couderc R Ann Biol Clin (Paris); 2005; 63(5):443-55. PubMed ID: 16230278 [TBL] [Abstract][Full Text] [Related]
18. Inflammation, oxidative stress, and atherosclerosis. Le NA Curr Opin Lipidol; 2004 Apr; 15(2):227-9. PubMed ID: 15017368 [No Abstract] [Full Text] [Related]
19. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Aliev G; Smith MA; Turmaine M; Neal ML; Zimina TV; Friedland RP; Perry G; LaManna JC; Burnstock G Exp Mol Pathol; 2001 Aug; 71(1):40-54. PubMed ID: 11502096 [TBL] [Abstract][Full Text] [Related]
20. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Oates JC; Gilkeson GS Clin Immunol; 2006 Dec; 121(3):243-50. PubMed ID: 16861040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]